1.Butler, J., G. M. Rocker, and S. Westaby, Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg, 1993. 55(2): p. 552–9.
2.Kollef, M. H., et al., The impact of nosocomial infections on patient outcomes following cardiac surgery. Chest, 1997. 112(3): p. 666–75.
3.Hortal, J., et al., Ventilator-associated pneumonia in patients undergoing major heart surgery: an incidence study in Europe. Crit Care, 2009. 13(3): p. R80.
4.Bouza, E., et al., Infections following major heart surgery in European intensive care units: there is room for improvement (ESGNI 007 Study). J Hosp Infect, 2006. 63(4): p. 399–405.
5.Leal-Noval, S. R., et al., Nosocomial pneumonia in patients undergoing heart surgery. Crit Care Med, 2000. 28(4): p. 935–40.
6.Kirklin, J. K., et al., Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg, 1983. 86(6): p. 845–57.
7.Sawa, Y., et al., Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. J Thorac Cardiovasc Surg, 1996. 111(1): p. 29–35.
8.Kharazmi, A., et al., Endotoxemia and enhanced generation of oxygen radicals by neutrophils from patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg, 1989. 98(3): p. 381–5.
9.Landow, L. and L. W. Andersen, Splanchnic ischaemia and its role in multiple organ failure. Acta Anaesthesiol Scand, 1994. 38(7): p. 626–39.
10.Hall, R. I., M. S. Smith, and G. Rocker, The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg, 1997. 85(4): p. 766–82.
11.Butler, J., et al., Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. J Thorac Cardiovasc Surg, 1993. 105(1): p. 25–30.
12.Hill, G. E., Cardiopulmonary bypass-induced inflammation: is it important? J Cardiothorac Vasc Anesth, 1998. 12(2 Suppl 1): p. 21–5.
13.Stoppelkamp, S., et al., Identification of Predictive Early Biomarkers for Sterile-SIRS after Cardiovascular Surgery. PLoS One, 2015. 10(8): p. e0135527.
14.Hadley, J. S., et al., Alterations in inflammatory capacity and TLR expression on monocytes and neutrophils after cardiopulmonary bypass. Shock, 2007. 27(5): p. 466–73.
15.Naldini, A., et al., In vitro cytokine production and T-cell proliferation in patients undergoing cardiopulmonary by-pass. Cytokine, 1995. 7(2): p. 165–70.
16.Lee, H., et al., Acupuncture for symptom management of rheumatoid arthritis: a pilot study. Clin Rheumatol, 2008. 27(5): p. 641–5.
17.Ng, D. K., et al., A double-blind, randomized, placebo-controlled trial of acupuncture for the treatment of childhood persistent allergic rhinitis. Pediatrics, 2004. 114(5): p. 1242–7.
18.Biernacki, W. and M. D. Peake, Acupuncture in treatment of stable asthma. Respir Med, 1998. 92(9): p. 1143–5.
19.Yang, L., et al., Cardioprotective effects of electroacupuncture pretreatment on patients undergoing heart valve replacement surgery: a randomized controlled trial. Ann Thorac Surg, 2010. 89(3): p. 781–6.
20.Ni, X., et al., Cardioprotective effect of transcutaneous electric acupoint stimulation in the pediatric cardiac patients: a randomized controlled clinical trial. Paediatr Anaesth, 2012. 22(8): p. 805–11.
21.Wang, J., et al., Electroacupuncture suppresses surgical trauma stress-induced lymphocyte apoptosis in rats. Neurosci Lett, 2005. 383(1–2): p. 68–72.
22.Cheng XD, W. G., et al., Dynamic observation on regulation of electroacupuncture on the proliferation responses of spleen lymphocytes from traumatized rats. Chin J Immunol, 1997(13): p. 68–70.
23.Cheng, X. D., et al., Effect of continued electroacupuncture on induction of interleukin–2 production of spleen lymphocytes from the injured rats. Acupunct Electrother Res, 1997. 22(1): p. 1–8.
24.XD, C., Involvement of orphanin FQ in electroacupuncture modulation on immunosuppression by trauma. Zhen Ci Yan Jiu, 2001(26): p. 219–20.
25.Yu, Y., et al., Role of endogenous interferon-gamma on the enhancement of splenic NK cell activity by electroacupuncture stimulation in mice. J Neuroimmunol, 1998. 90(2): p. 176–86.
26.Wang, K., et al., The effects of electroacupuncture on TH1/TH2 cytokine mRNA expression and mitogen-activated protein kinase signaling pathways in the splenic T cells of traumatized rats. Anesth Analg, 2009. 109(5): p. 1666–73.
27.Zhang, Q., et al., The effect of pre-treatment with transcutaneous electrical acupoint stimulation on the quality of recovery after ambulatory breast surgery: a prospective, randomised controlled trial. Anaesthesia, 2014. 69(8): p. 832–9.
28.Man, K. M., et al., Transcutaneous electrical nerve stimulation on ST36 and SP6 acupoints prevents hyperglycaemic response during anaesthesia: a randomised controlled trial. Eur J Anaesthesiol, 2011. 28(6): p. 420–6.
29.Wang, H., et al., Transcutaneous electric acupoint stimulation reduces intra-operative remifentanil consumption and alleviates postoperative side-effects in patients undergoing sinusotomy: a prospective, randomized, placebo-controlled trial. Br J Anaesth, 2014. 112(6): p. 1075–82.
30.Yeh, M. L., et al., Effect of Transcutaneous Acupoint Electrical Stimulation on Post-Hemorrhoidectomy-Associated Pain, Anxiety, and Heart Rate Variability: A Randomized-Controlled Study. Clin Nurs Res, 2018. 27(4): p. 450–466.
31.Grech, D., et al., Intraoperative Low-frequency Electroacupuncture under General Anesthesia Improves Postoperative Recovery in a Randomized Trial. J Acupunct Meridian Stud, 2016. 9(5): p. 234–241.
32.Roche, P. A. and K. Furuta, The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol, 2015. 15(4): p. 203–16.
33.Hotchkiss, R. S., G. Monneret, and D. Payen, Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis, 2013. 13(3): p. 260–8.
34.Monneret, G., et al., Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med, 2008. 14(1–2): p. 64–78.
35.Boomer, J. S., et al., Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA, 2011. 306(23): p. 2594–605.
36.Cheron, A., et al., Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma. Crit Care, 2010. 14(6): p. R208.
37.Venet, F., et al., Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock. Crit Care Med, 2007. 35(8): p. 1910–7.
38.Ho, Y. P., et al., A strong association between down-regulation of HLA-DR expression and the late mortality in patients with severe acute pancreatitis. Am J Gastroenterol, 2006. 101(5): p. 1117–24.
39.Satoh, A., et al., Human leukocyte antigen-DR expression on peripheral monocytes as a predictive marker of sepsis during acute pancreatitis. Pancreas, 2002. 25(3): p. 245–50.
40.Reinke, P., et al., Late acute rejection in long-term renal allograft recipients. Diagnostic and predictive value of circulating activated T cells. Transplantation, 1994. 58(1): p. 35–41.
41.Antoniades, C. G., et al., Reduced monocyte HLA-DR expression: a novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure. Hepatology, 2006. 44(1): p. 34–43.
42.Ahlstrom, A., et al., Predictive value of interleukins 6, 8 and 10, and low HLA-DR expression in acute renal failure. Clin Nephrol, 2004. 61(2): p. 103–10.
43.Meisel, A., et al., Predicting post-stroke infections and outcome with blood-based immune and stress markers. Cerebrovasc Dis, 2012. 33(6): p. 580–8.
44.Venet, F., et al., Decreased Monocyte HLA-DR Expression in Patients After Non-Shockable out-of-Hospital Cardiac Arrest. Shock, 2016. 46(1): p. 33–6.
45.Haeusler, K. G., et al., Immune responses after acute ischemic stroke or myocardial infarction. Int J Cardiol, 2012. 155(3): p. 372–7.
46.Schefold, J. C., et al., Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol, 2016. 12(10): p. 610–23.
47.von Haehling, S., et al., Leukocyte redistribution: effects of beta blockers in patients with chronic heart failure. PLoS One, 2009. 4(7): p. e6411.
48.Monneret, G., et al., Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med, 2006. 32(8): p. 1175–83.
49.Franke, A., et al., Delayed recovery of human leukocyte antigen-DR expression after cardiac surgery with early non-lethal postoperative complications: only an epiphenomenon? Interact Cardiovasc Thorac Surg, 2008. 7(2): p. 207–11.
50.Allen, M. L., et al., Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit Care Med, 2002. 30(5): p. 1140–5.
51.Bianchi, M. E. and A. A. Manfredi, High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev, 2007. 220: p. 35–46.
52.Zhang, J., et al., Vagal modulation of high mobility group box–1 protein mediates electroacupuncture-induced cardioprotection in ischemia-reperfusion injury. Sci Rep, 2015. 5: p. 15503.
53.Wild, C. A., et al., HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol, 2012. 24(8): p. 485–94.
54.Zhang, Y., et al., The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res, 2011. 31(2): p. 249–57.
55.Shevach, E. M., et al., Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev, 2001. 182: p. 58–67.
56.Allan, S. E., et al., CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev, 2008. 223: p. 391–421.
57.Yeh, C. H., et al., Induced interleukin–19 contributes to cell-mediated immunosuppression in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Ann Thorac Surg, 2011. 92(4): p. 1252–9.